预测代谢功能障碍相关脂肪性肝病相关肝硬化患者的肝功能失代偿:ABID-LSM模型
本研究为多中心回顾性队列,纳入388例代偿期代谢功能障碍相关脂肪性肝病(MASLD)相关肝硬化患者,其中273例(70.4%)有肝脏硬度测量(LSM)数据。随访中位31个月(范围20-60个月)期间54例(20%)发生肝功能失代偿。整合LSM的ABID-LSM模型5年预测准确度优于ABIDE、LSM及其他现有模型,切点8.1可区分5年肝功能失代偿高风险与低风险患者。
要点
- ABID-LSM模型5年时间依赖AUC为0.80,优于ABIDE的0.75(p=0.03)和LSM的0.63(p<0.001)。
- 切点8.1区分5年肝功能失代偿高风险与低风险患者:24% vs 5%(sHR=4.8,p<0.001)。
- ABID-LSM模型5年预测能力优于ALBI、FIB-4、NAFLD Decompensation Risk Score和ANTICIPATE模型(均p<0.001)。
核心结论
- ABID-LSM模型预测MASLD相关肝硬化患者肝功能失代偿的准确度高于现有预测模型。
- 若经外部验证,ABID-LSM或可识别能从药物治疗和密切监测中获益的患者。
研究设计与样本
- 多中心回顾性队列,纳入代偿期MASLD相关肝硬化患者,采用竞争风险回归评估失代偿发生率。
- 共388例患者,其中273例(70.4%)有可用的LSM数据。
- 通过时间依赖AUC(tAUC)评估整合LSM的改良ABIDE模型(ABID-LSM)的预测准确度,并与其他预测模型比较。
主要发现
- 随访中位31个月(范围20-60个月)期间,54例(20%)患者发生肝功能失代偿。
- ABID-LSM模型5年预测准确度(tAUC 0.80)优于ABIDE(tAUC 0.75,p=0.03)和LSM(tAUC 0.63,p<0.001)。
- ABID-LSM模型校准良好(斜率0.99),整体性能优异(Integrated Brier Score 0.15)。
- 切点8.1区分5年肝功能失代偿高风险与低风险患者:24% vs 5%(sHR=4.8,p<0.001)。
- ABID-LSM模型5年预测能力优于ALBI、FIB-4、NAFLD Decompensation Risk Score和ANTICIPATE模型(均p<0.001),也优于肝静脉压力梯度测量(tAUC 0.78 vs 0.71,p<0.001,n=60)。
关键数值与推荐
- ABID-LSM模型5年tAUC为0.80,ABIDE为0.75(p=0.03),LSM为0.63(p<0.001)。
- 切点8.1:5年肝功能失代偿高风险组24% vs 低风险组5%(sHR=4.8,p<0.001)。
- ABID-LSM模型校准斜率0.99,Integrated Brier Score 0.15。
- 与肝静脉压力梯度测量比较:ABID-LSM tAUC 0.78 vs 0.71(p<0.001,n=60)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论提出若经外部验证,ABID-LSM或可识别能从药物治疗和密切监测中获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Predicting the risk of hepatic decompensation guides prognostication and therapy; however, it is challenging in patients with cirrhosis due to metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to improve a previously developed predictive tool of hepatic decompensation in MASLD cirrhosis (ABIDE) by incorporating liver stiffness measurement (LSM). METHODS: A multi-centre retrospective cohort of patients with compensated cirrhosis due to MASLD was identified, with decompensation incidence assessed using competing risk regression. The prognostic accuracy of a modified ABIDE model incorporating LSM (ABID-LSM) was assessed using time-dependent AUC (tAUC) and compared with other predictive models. RESULTS: Out of 388 patients, 273 (70.4%) had available LSM. Hepatic decompensation occurred in 54 (20%) patients during follow-up (median 31 months, range: 20-60). The predictive accuracy at 5 years of ABID-LSM (tAUC 0.80) was better than ABIDE (tAUC 0.75, p = 0.03) and LSM (tAUC 0.63, p < 0.001). The ABID-LSM model calibrated well (slope 0.99) with excellent overall performance (Integrated Brier Score 0.15). A cut-off of 8.1 separated those at high and low risk of hepatic decompensation at 5 years (24% vs. 5%, respectively, sHR = 4.8, p < 0.001). The ABID-LSM model had better predictive ability at 5 years than ALBI, FIB-4, NAFLD Decompensation Risk Score and ANTICIPATE models (all p < 0.001) as well as hepatic vein pressure gradient measurement (tAUC 0.78 vs. 0.71, p < 0.001, n = 60). CONCLUSIONS: The ABID-LSM model has greater accuracy in predicting hepatic decompensation in patients with cirrhosis due to MASLD than existing predictive models. If externally validated, ABID-LSM may identify those who benefit from pharmacotherapy and close monitoring.
引用
- Calzadilla Bertot L, Sòria A, Jimenez-Masip A, et al. Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease-Related Cirrhosis: The ABID-LSM Model. Aliment Pharmacol Ther. 2025. PMID: 40491328. doi:10.1111/apt.70215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。